4.8 Article

Sustained epidermal powder drug delivery via skin microchannels

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 249, Issue -, Pages 94-102

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.01.030

Keywords

Transdermal drug delivery; Laser; Micropore; Microporation; Microchannel; Microneedle

Funding

  1. National Institutes of Health [DA033371, AI107678]
  2. Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103430]
  3. National Science Foundation EPSCoR Cooperative [EPS1004057]
  4. Office of Integrative Activities
  5. Office Of The Director [1004057] Funding Source: National Science Foundation

Ask authors/readers for more resources

Transdermal delivery of hydrophilic drugs is challenging. This study presents a novel sustained epidermal powder delivery technology (sEPD) for safe, efficient, and sustained delivery of hydrophilic drugs across the skin. sEPD is based on coating powder drugs into high-aspect-ratio, micro-coating channels (MCCs) followed by topical application of powder drug-coated array patches onto ablative fractional laser-generated skin MCs to deliver drugs into the skin. We found sEPD could efficiently deliver chemical drugs without excipients and biologics drugs in the presence of sugar excipients into the skin with a duration of similar to 12h. Interestingly the sEPD significantly improved zidovudine bioavailability by similar to 100% as compared to oral gavage delivery. sEPD of insulin was found to maintain blood glucose levels in normal range for at least 6 h in chemical-induced diabetes mice, while subcutaneous injection failed to maintain blood glucose levels in normal range. sEPD of anti-programmed death-1 antibody showed more potent anti-tumor efficacy than intraperitoneal injection in B16F10 melanoma models. Tiny skin MCs and 'bulk' drug powder inside relatively deep MCCs are crucial to induce the sustained drug release. The improved bioavailability and functionality warrants further development of the novel sEPD for clinical use. (C) 2017 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available